Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From Therapy to Cancer Prevention Using HRD Testing on Patients with High-grade Ovarian Cancer.

Cancer prevention research (Philadelphia, Pa.) - 1 Jul 2025

Tibiletti Maria Grazia, Carnevali Ileana, Facchi Sofia, Pensotti Valeria, Formenti Giorgio, Sahnane Nora, Libera Laura, Ronchi Susanna, Volorio Sara, Pierotti Marco Alessandro, La Rosa Stefano, Sessa Fausto

Abstract excerpt

Approximately half of high-grade ovarian cancers are characterized by genetic and epigenetic alterations in genes involved in homologous recombination repair (HRR), most commonly BRCA1 and BRCA2. HRR defects (HRD) identified by tests of genomic instability confer PARP inhibitor sensitivity in ovarian cancers. Commercial tests that combine tumor BRCA testing with a genomic instability score (HRD test) are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomic Instability

Share to Germ-Line Mutation

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Recombinational DNA Repair

Source

Identifiers

PMID: 40244633
DOI: 10.1158/1940-6207.CAPR-24-0474

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From Therapy to Cancer Prevention Using HRD Testing on Patients with High-grade Ovarian Cancer.PMID 40244633Read ↗

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literatureSemantic proximity Read ↗

Homologous recombination deficiency-driven genomic instability in ovarian cancer as an indicator of BRCA1 and BRCA2 variant pathogenicity.Semantic proximity Read ↗

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trialSemantic proximity Read ↗

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?Semantic proximity Read ↗

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian CancerSemantic proximity Read ↗

Clinical assays for assessment of homologous recombination DNA repair deficiency.Semantic proximity Read ↗

HRDetect in Ovarian Carcinoma: Stratification and Therapeutic ImplicationsSemantic proximity Read ↗

Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian CancerSemantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literatureSemantic proximity Read ↗

The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.Semantic proximity Read ↗

A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.